Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

Takeshi Yoshida, Isamu Okamoto, Wataru Okamoto, Erina Hatashita, Yuki Yamada, Kiyoko Kuwata, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as gefitinib and erlotinib in non-small cell lung cancer (NSCLC) is often limited by the emergence of drug resistance conferred either by a secondary T790M mutation of EGFR or by acquired amplification of the MET gene. We now show that the extent of activation of the tyrosine kinase Src is markedly increased in gefitinib-resistant NSCLC (HCC827 GR) cells with MET amplification compared with that in the gefitinib-sensitive parental (HCC827) cells. In contrast, the extent of Src activation did not differ between gefitinib-resistant NSCLC (PC9/ZD) cells harboring the T790M mutation of EGFR and the corresponding gefitinib-sensitive parental (PC9) cells. This activation of Src in HCC827 GR cells was largely abolished by the MET-TKI PHA-665752 but was only partially inhibited by gefitinib, suggesting that Src activation is more dependent on MET signaling than on EGFR signaling in gefitinib-resistant NSCLC cells with MET amplification. Src inhibitors blocked Akt and Erk signaling pathways, resulting in both suppression of cell growth and induction of apoptosis, in HCC827 GR cells as effectively as did the combination of gefitinib and PHA-665752. Furthermore, Src inhibitor dasatinib inhibited tumor growth in HCC827 GR xenografts to a significantly greater extent than did treatment with gefitinib alone. These results provide a rationale for clinical targeting of Src in gefitinib-resistant NSCLC with MET amplification.

Original languageEnglish
Pages (from-to)167-172
Number of pages6
JournalCancer Science
Volume101
Issue number1
DOIs
Publication statusPublished - Jan 1 2010

Fingerprint

Growth Inhibitors
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
gefitinib
Mutation
src-Family Kinases
Gene Amplification
Growth
Drug Resistance
Heterografts
Protein-Tyrosine Kinases
Apoptosis

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. / Yoshida, Takeshi; Okamoto, Isamu; Okamoto, Wataru; Hatashita, Erina; Yamada, Yuki; Kuwata, Kiyoko; Nishio, Kazuto; Fukuoka, Masahiro; Jänne, Pasi A.; Nakagawa, Kazuhiko.

In: Cancer Science, Vol. 101, No. 1, 01.01.2010, p. 167-172.

Research output: Contribution to journalArticle

Yoshida, Takeshi ; Okamoto, Isamu ; Okamoto, Wataru ; Hatashita, Erina ; Yamada, Yuki ; Kuwata, Kiyoko ; Nishio, Kazuto ; Fukuoka, Masahiro ; Jänne, Pasi A. ; Nakagawa, Kazuhiko. / Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. In: Cancer Science. 2010 ; Vol. 101, No. 1. pp. 167-172.
@article{477084da098742bb9f2ab69054345d0b,
title = "Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification",
abstract = "The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as gefitinib and erlotinib in non-small cell lung cancer (NSCLC) is often limited by the emergence of drug resistance conferred either by a secondary T790M mutation of EGFR or by acquired amplification of the MET gene. We now show that the extent of activation of the tyrosine kinase Src is markedly increased in gefitinib-resistant NSCLC (HCC827 GR) cells with MET amplification compared with that in the gefitinib-sensitive parental (HCC827) cells. In contrast, the extent of Src activation did not differ between gefitinib-resistant NSCLC (PC9/ZD) cells harboring the T790M mutation of EGFR and the corresponding gefitinib-sensitive parental (PC9) cells. This activation of Src in HCC827 GR cells was largely abolished by the MET-TKI PHA-665752 but was only partially inhibited by gefitinib, suggesting that Src activation is more dependent on MET signaling than on EGFR signaling in gefitinib-resistant NSCLC cells with MET amplification. Src inhibitors blocked Akt and Erk signaling pathways, resulting in both suppression of cell growth and induction of apoptosis, in HCC827 GR cells as effectively as did the combination of gefitinib and PHA-665752. Furthermore, Src inhibitor dasatinib inhibited tumor growth in HCC827 GR xenografts to a significantly greater extent than did treatment with gefitinib alone. These results provide a rationale for clinical targeting of Src in gefitinib-resistant NSCLC with MET amplification.",
author = "Takeshi Yoshida and Isamu Okamoto and Wataru Okamoto and Erina Hatashita and Yuki Yamada and Kiyoko Kuwata and Kazuto Nishio and Masahiro Fukuoka and J{\"a}nne, {Pasi A.} and Kazuhiko Nakagawa",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1349-7006.2009.01368.x",
language = "English",
volume = "101",
pages = "167--172",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification

AU - Yoshida, Takeshi

AU - Okamoto, Isamu

AU - Okamoto, Wataru

AU - Hatashita, Erina

AU - Yamada, Yuki

AU - Kuwata, Kiyoko

AU - Nishio, Kazuto

AU - Fukuoka, Masahiro

AU - Jänne, Pasi A.

AU - Nakagawa, Kazuhiko

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as gefitinib and erlotinib in non-small cell lung cancer (NSCLC) is often limited by the emergence of drug resistance conferred either by a secondary T790M mutation of EGFR or by acquired amplification of the MET gene. We now show that the extent of activation of the tyrosine kinase Src is markedly increased in gefitinib-resistant NSCLC (HCC827 GR) cells with MET amplification compared with that in the gefitinib-sensitive parental (HCC827) cells. In contrast, the extent of Src activation did not differ between gefitinib-resistant NSCLC (PC9/ZD) cells harboring the T790M mutation of EGFR and the corresponding gefitinib-sensitive parental (PC9) cells. This activation of Src in HCC827 GR cells was largely abolished by the MET-TKI PHA-665752 but was only partially inhibited by gefitinib, suggesting that Src activation is more dependent on MET signaling than on EGFR signaling in gefitinib-resistant NSCLC cells with MET amplification. Src inhibitors blocked Akt and Erk signaling pathways, resulting in both suppression of cell growth and induction of apoptosis, in HCC827 GR cells as effectively as did the combination of gefitinib and PHA-665752. Furthermore, Src inhibitor dasatinib inhibited tumor growth in HCC827 GR xenografts to a significantly greater extent than did treatment with gefitinib alone. These results provide a rationale for clinical targeting of Src in gefitinib-resistant NSCLC with MET amplification.

AB - The efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as gefitinib and erlotinib in non-small cell lung cancer (NSCLC) is often limited by the emergence of drug resistance conferred either by a secondary T790M mutation of EGFR or by acquired amplification of the MET gene. We now show that the extent of activation of the tyrosine kinase Src is markedly increased in gefitinib-resistant NSCLC (HCC827 GR) cells with MET amplification compared with that in the gefitinib-sensitive parental (HCC827) cells. In contrast, the extent of Src activation did not differ between gefitinib-resistant NSCLC (PC9/ZD) cells harboring the T790M mutation of EGFR and the corresponding gefitinib-sensitive parental (PC9) cells. This activation of Src in HCC827 GR cells was largely abolished by the MET-TKI PHA-665752 but was only partially inhibited by gefitinib, suggesting that Src activation is more dependent on MET signaling than on EGFR signaling in gefitinib-resistant NSCLC cells with MET amplification. Src inhibitors blocked Akt and Erk signaling pathways, resulting in both suppression of cell growth and induction of apoptosis, in HCC827 GR cells as effectively as did the combination of gefitinib and PHA-665752. Furthermore, Src inhibitor dasatinib inhibited tumor growth in HCC827 GR xenografts to a significantly greater extent than did treatment with gefitinib alone. These results provide a rationale for clinical targeting of Src in gefitinib-resistant NSCLC with MET amplification.

UR - http://www.scopus.com/inward/record.url?scp=71849120012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849120012&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2009.01368.x

DO - 10.1111/j.1349-7006.2009.01368.x

M3 - Article

C2 - 19804422

AN - SCOPUS:71849120012

VL - 101

SP - 167

EP - 172

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -